Investors Buy Chemours Company (The) (CC) on Weakness

Investors bought shares of Chemours Company (The) (NYSE:CC) on weakness during trading hours on Friday. $143.50 million flowed into the stock on the tick-up and $96.72 million flowed out of the stock on the tick-down, for a money net flow of $46.78 million into the stock. Of all stocks tracked, Chemours Company (The) had the 8th highest net in-flow for the day. Chemours Company (The) traded down ($3.67) for the day and closed at $52.16

Several analysts have recently issued reports on CC shares. Zacks Investment Research cut shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. BidaskClub raised shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Wednesday, July 12th. Jefferies Group LLC reissued a “buy” rating and set a $50.00 price target (up previously from $48.00) on shares of Chemours Company (The) in a research report on Thursday, July 13th. Citigroup Inc increased their price target on shares of Chemours Company (The) from $45.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. Finally, J P Morgan Chase & Co increased their price target on shares of Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a research report on Friday, August 4th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $53.88.

The company has a market cap of $9.64 billion and a price-to-earnings ratio of 19.80. The company has a current ratio of 1.97, a quick ratio of 1.48 and a debt-to-equity ratio of 7.09.

Chemours Company (The) (NYSE:CC) last issued its earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.01 by $0.11. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.59 billion. Chemours Company (The) had a net margin of 4.86% and a return on equity of 155.80%. The firm’s revenue was up 13.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.61 earnings per share. equities research analysts forecast that Chemours Company will post 3.63 EPS for the current year.

In related news, insider E Bryan Snell sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $46.24, for a total value of $462,400.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Amy Trojanowski sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $46.03, for a total transaction of $115,075.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 77,142 shares of company stock worth $3,953,265. 1.14% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Financial Architects Inc raised its holdings in Chemours Company (The) by 1,230.3% during the second quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock worth $111,000 after purchasing an additional 2,719 shares in the last quarter. Acrospire Investment Management LLC raised its holdings in Chemours Company (The) by 3.4% during the second quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock worth $117,000 after purchasing an additional 100 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in Chemours Company (The) by 2,138.8% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock worth $118,000 after purchasing an additional 2,973 shares in the last quarter. Smithfield Trust Co. raised its holdings in Chemours Company (The) by 521.4% during the second quarter. Smithfield Trust Co. now owns 4,791 shares of the specialty chemicals company’s stock worth $182,000 after purchasing an additional 4,020 shares in the last quarter. Finally, Alps Advisors Inc. acquired a new stake in Chemours Company (The) during the second quarter worth approximately $202,000. 72.99% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/11/04/investors-buy-chemours-company-the-cc-on-weakness.html.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

What are top analysts saying about Chemours Company (The)? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemours Company (The) and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit